Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07500766

Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Introduction:

Male hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil.

Objective:

To evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism.

Methods:

This is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction.

Outcomes:

The primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng/dL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence.

Clinical Significance:

This study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction.

Relevance and Impact:

This is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Absence of desire for future fertility.
  • Two fasting total testosterone measurements ≤ 350 ng/dL obtained between 6:00 and 10:00 a.m.
  • A positive ADAM questionnaire result (Participants with a prior diagnosis of testosterone deficiency established at this institution who are currently receiving testosterone replacement therapy and wish to participate in the study will be eligible for inclusion after completion of an appropriate washout period of the testosterone formulation in use.)

Exclusion criteria

  • Inability to complete or respond to study questionnaires.
  • Body mass index (BMI) > 35 kg/m².
  • Untreated depression, defined as a Beck Depression Inventory score > 20.
  • Personal history of cancer.
  • Suspicious findings on digital rectal examination or breast examination.
  • Prostate-specific antigen (PSA) > 4 ng/mL.
  • History of thrombosis.
  • Known thrombophilia.
  • Erythrocytosis.
  • Polycythemia.
  • Elevated liver enzymes (AST or ALT > 1.5 times the upper limit of normal).
  • Untreated chronic disease.
  • Heart failure classified as New York Heart Association (NYHA) class III or IV.
  • History of cardiovascular disease within the previous 6 months.
  • Substance use disorder or alcohol dependence.
  • Use of antiandrogen medications (flutamide, bicalutamide, enzalutamide, apalutamide, spironolactone, cyproterone acetate, abiraterone, ketoconazole, dutasteride, finasteride).
  • Use of estrogenic medications (estradiol, conjugated estrogens, progestogens).
  • Use of anabolic androgenic steroids without medical indication.
  • Untreated hypothyroidism.
  • Known allergy or hypersensitivity to testosterone or any component of the implant (testosterone, stearic acid).

Treatment and study plan

Subcutaneous Testosterone Implants

Drug

Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Primary outcomes

  1. Testosterone 200mg implants in hypogonadal men pharmacokinetics

    Time frame: 180 days

    To evaluate the efficacy of a resorbable subcutaneous testosterone implant (200 mg), administered at a total dose of 800 mg (four 200-mg implants), in achieving and maintaining total serum testosterone concentration between 450 and 800 ng/dL in symptomatic hypogonadal men over a 180-day period

Secondary outcomes

  1. Maximum Plasma Testosterone Concentration

    Time frame: Up to 180 days

    Assessment of the maximum plasma concentration of total testosterone.

  2. Time to Maximum Plasma Testosterone Concentration (Tmax)

    Time frame: Up to 180 days

    Assessment of the time required to reach the maximum plasma concentration of total testosterone after implantation.

  3. Plasma Testosterone Elimination Half-Life (T½)

    Time frame: Up to 180 days

    Assessment of the elimination half-life of total testosterone in plasma following implantation.

  4. Average Plasma Testosterone Concentration (Cavg)

    Time frame: Up to 180 days

    Assessment of the average plasma concentration of total testosterone following implantation.

  5. Area Under the Plasma Concentration-Time Curve

    Time frame: Up to 180 days

    Assessment of the area under the curve of plasma concentration.

  6. To evaluate the safety profile of testosterone implants.

    Time frame: 180 days

    Evaluate the incidence of complications in a clavien dindo scale

  7. Change in Serum Luteinizing Hormone (LH) Levels

    Time frame: Up to 180 days

    Assessment of changes in serum luteinizing hormone (LH) levels during treatment with testosterone implants.

  8. Evaluation of sexual outcomes

    Time frame: 180 days

    To evaluate the incidence of erectile dysfunction withe the International Index of Erectile Function.

  9. Evaluation of coagulation after testosterone implants

    Time frame: 180 days

    Evaluate the plasma thromboelastography in men treated with testosterone implants.

  10. Change in Hypogonadal Symptoms Assessed by the Androgen Deficiency in the Aging Male Questionnaire

    Time frame: Up to 180 days

    Assessment of changes in hypogonadal symptoms using the Androgen Deficiency in the Aging Male questionnaire.

  11. To evaluate changes in quality of life in hypogonadal patients undergoing testosterone replacement therapy with implants

    Time frame: 180 days

    To evaluate changes in quality of life in hypogonadal patients undergoing testosterone replacement therapy with implants with the World Health Organization Quality of Life - BREF (WHOQOL-BREF) assessment questionnaire score.

  12. To evaluate the metabolic effects of testosterone implants using serum lipid profile

    Time frame: 180 days

    To evaluate the metabolic effects of testosterone implants on the serum lipid profile

  13. To assess patient satisfaction with testosterone implant therapy.

    Time frame: 180 days

    To assess patient satisfaction with a numerical Likert scale 1 to 5

  14. To compare patient satisfaction with testosterone implants versus other testosterone replacement therapy modalities previously used by the participants.

    Time frame: 180 days

    To compare patient satisfaction with testosterone implants versus other testosterone replacement therapy modalities previously used by the participants, with a qualitative comprehensive questionnaire and a numerical final grade from 1 to 100

  15. Change in Serum Follicle-Stimulating Hormone (FSH) Levels

    Time frame: Up to 180 days

    Assessment of changes in serum follicle-stimulating hormone (FSH) levels during treatment with testosterone implants.

  16. Change in Prostate-Specific Antigen (PSA) Levels

    Time frame: Up to 180 days

    Assessment of changes in serum prostate-specific antigen (PSA) levels during treatment with testosterone implants.

  17. To evaluate patient regret with testosterone implant treatment

    Time frame: 180 days

    Evaluate the incidence of regret in the use of testosterone implant treatment in a 1-5 Likert scale.

  18. To evaluate the metabolic effects of testosterone implants on body mass index (BMI)

    Time frame: 180 days

    To evaluate the metabolic effects of testosterone implants on body mass index in kg/m2 (BMI)

  19. To evaluate the metabolic effects of testosterone implants on waist circumference.

    Time frame: 180 days

    To evaluate the metabolic effects of testosterone implants on the measure of waist circumference in centimeters (cm).

Study contacts

Contact information is provided by the study sponsor or research team.

Bruno N PhD, MD

CONTACT

[email protected]

+5511999686655

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Mar 30, 2026
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.